Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
This study will characterize the safety, tolerability, biological activity, and pharmacokinetics of LBH589 in Japanese patients with advanced solid tumors whose disease has progressed despite standard therapies, or for whom no standard therapy exists.
Cancer|Advanced Solid Tumor
DRUG: LBH589
To characterize the safety and tolerability of LBH589, including acute and chronic toxicities in Japanese patients with advanced solid tumors., First cycle
To characterize the pharmacokinetics (PK) of LBH589, First cycle|To evaluate any antitumor activity of LBH589 in patients with advanced solid tumors, Every 2 cycle
This study will characterize the safety, tolerability, biological activity, and pharmacokinetics of LBH589 in Japanese patients with advanced solid tumors whose disease has progressed despite standard therapies, or for whom no standard therapy exists.